'Disease free survival' presentation slideshows

COH603: Public Health Biology

Class 6: Wednesday, June 19 2013. COH603: Public Health Biology. Chronic Disease. Cancer Type II Diabetes. Cancer. Unregulated cell growth Genetic Instability is a hallmark of cancer. DNA Facts. There are 3 billion letters in your DNA code in every cell of your body.

984 views • 90 slides

Breast Cancer Patient Issues in Family Practice: An Interactive Session

Breast Cancer Patient Issues in Family Practice: An Interactive Session. Acknowledgements. Content Development Committee Sunil Verma, MD, MSEd, FRCPC Lisa Del Giudice, MSc, MD, CCFP Medical Oncologist, Staff Division of Medical Department of Family Medicine

1.18k views • 89 slides

Trial design and patient recruitment

935 views • 69 slides

Management of Locally Advanced NSCLC

Management of Locally Advanced NSCLC. Shilpen Patel MD FACRO Department of Radiation Oncology, University of Washington, Seattle, WA. Roadmap. Background Evolution of therapy Radiation alone Sequential chemotherapy and radiation Concurrent chemotherapy and radiation

831 views • 66 slides

Management of Locally Advanced NSCLC

Management of Locally Advanced NSCLC. Shilpen Patel MD FACRO Department of Radiation Oncology, University of Washington, Seattle, WA. Roadmap. Background Evolution of therapy Radiation alone Sequential chemotherapy and radiation Concurrent chemotherapy and radiation

804 views • 66 slides

Trastuzumab plus chemotherapy: the gold standard for HER2 positive early breast cancer

Current status of adjuvant HER2 targeting therapy Valentina Guarneri, MD, PhD Istituto Oncologico Veneto IRCCS University of Padova. Outline. Trastuzumab plus chemotherapy: the gold standard for HER2 positive early breast cancer

1.09k views • 60 slides

Adjuvante therapie van het coloncarcinoom anno 2004-2005: is 5FU/LV nog steeds de standaard?

Adjuvante therapie van het coloncarcinoom anno 2004-2005: is 5FU/LV nog steeds de standaard?. Prof.dr. C.J.A. Punt afd. Medische Oncologie UMC St. Radboud Nijmegen. Adjuvant therapy for colon cancer hot topics 2004. FOLFOX Capecitabine Stage II Primary endpoint in randomised studies.

619 views • 51 slides

POSTOPERATIVE MANAGEMENT Of DTC

POSTOPERATIVE MANAGEMENT Of DTC. MS,Hosseini ,Associate Professor Of Endocrinology, Baqiyatallah University of Medical Science. Agenda. INITIAL MANAGEMENT Postoperative remnant ablation TSH suppression therapy LONG-TERM MANAGEMENT Serum Tg measurement

624 views • 46 slides

Highlights of the Day: Colorectal Cancer

Highlights of the Day: Colorectal Cancer. Charles D. Blanke, M.D. OHSU Cancer Institute. Colorectal Cancer Highlights. Background and epidemiology Key findings in adjuvant treatment of colorectal cancer Key findings in metastatic colorectal cancer Future directions Conclusions.

713 views • 36 slides

440 views • 35 slides

Adjuvant Treatment Tamoxifen and Aromatase Inhibitors: EFFICACY

505 views • 31 slides

Julie R. Gralow, M.D. Director, Breast Medical Oncology, Seattle Cancer Care Alliance

Breast Cancer Systemic Therapy for Early Stage Disease. Julie R. Gralow, M.D. Director, Breast Medical Oncology, Seattle Cancer Care Alliance Professor, Medical Oncology, University of Washington School of Medicine Member, Clinical Division, Fred Hutchinson Cancer Research Center.

402 views • 28 slides

Julie R. Gralow, M.D. Director, Breast Medical Oncology, Seattle Cancer Care Alliance

Breast Cancer Systemic Therapy for Early Stage Disease. Julie R. Gralow, M.D. Director, Breast Medical Oncology, Seattle Cancer Care Alliance Professor, Medical Oncology, University of Washington School of Medicine Member, Clinical Division, Fred Hutchinson Cancer Research Center.

416 views • 28 slides

Liver Metastases

Liver Metastases. Jean-Bernard Poulard MD, MBA, FACS Mount Sinai School of Medicine Queens Hospital Center Jamaica, NY. Liver Metastases. Liver Metastases. 30 Years Ago, Considered Incurable. Liver Metastasis. Extent of the problem Primary Cancers and Mets

710 views • 26 slides

Nicholas Petrelli, M.D.

EORTC INTERGROUP 40983 : Perioperative FOLFOX4 for Potentially Resectable Colorectal Liver Metastases, Nordlinger,B et al June 4, 2007 Discussant Nicholas Petrelli, MD Helen F Graham Cancer Center. Nicholas Petrelli, M.D. No Financial Interests to Disclose.

425 views • 24 slides

R. D. Issels, L.Lindner, Munich, Germany P. Hohenberger, Berlin/Mannheim, Germany

13th Annual CTOS Meeting. EARLY PROGRESSION IN PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS AN ANALYSIS FROM A PHASE III RANDOMIZED PROSPECTIVE TRIAL (EORTC 62961/ESHO) OF NEOADJUVANT CHEMOTHERAPY WITH OR WITHOUT REGIONAL HYPERTHERMIA (RHT).

398 views • 23 slides

R. D. Issels, L.Lindner, Munich, Germany P. Hohenberger, Berlin/Mannheim, Germany

13th Annual CTOS Meeting. EARLY PROGRESSION IN PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS AN ANALYSIS FROM A PHASE III RANDOMIZED PROSPECTIVE TRIAL (EORTC 62961/ESHO) OF NEOADJUVANT CHEMOTHERAPY WITH OR WITHOUT REGIONAL HYPERTHERMIA (RHT).

318 views • 23 slides

Preliminary Results: A randomised, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer - CONKO*-001 -.

379 views • 21 slides

OBJECTIVE :

Figure 1. 1.0. 0.9. 0.8. 0.7. Disease Free Survival. 0.6. S S+RT. p = 0.59. 0.5. Fraction Surviving. 0.4. Overall Survival. S S+RT. p = 0.92. 0.3. 0.2. 0.1. 0.0. 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. Time, years.

145 views • 1 slides

Supplementary Figure 1 Gattolliat et al

Supplementary Figure 1 Gattolliat et al. Overall survival. Disease -free survival. High miR -487b. High miR -487b. Disease-free surviving (%). Patient surviving (%). Low miR-487b. Low miR-487b. P=0.0671. P=0.0589. Overall survival (months). Disease-Free survival (months).

95 views • 1 slides